These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 30926258)

  • 21. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    BMJ; 2011 Nov; 343():d6898. PubMed ID: 22115901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
    Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
    BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.
    Noh RM; Graveling AJ; Frier BM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
    Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
    Diabetes Obes Metab; 2018 Sep; 20(9):2131-2139. PubMed ID: 29722116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early cardiovascular risk and all-cause mortality following an incident of severe hypoglycaemia: A population-based cohort study.
    Lo SC; Yang YS; Kornelius E; Huang JY; Lai YR; Huang CN; Chiou JY
    Diabetes Obes Metab; 2019 Aug; 21(8):1878-1885. PubMed ID: 30972910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The science of hypoglycemia in patients with diabetes.
    Oyer DS
    Curr Diabetes Rev; 2013 May; 9(3):195-208. PubMed ID: 23506375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.
    Nunes AP; Iglay K; Radican L; Engel SS; Yang J; Doherty MC; Dore DD
    Diabetes Obes Metab; 2017 Oct; 19(10):1425-1435. PubMed ID: 28497592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
    Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
    Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey.
    Akram K; Pedersen-Bjergaard U; Carstensen B; Borch-Johnsen K; Thorsteinsson B
    Diabet Med; 2006 Jul; 23(7):750-6. PubMed ID: 16842479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study.
    Sämann A; Mühlhauser I; Bender R; Kloos Ch; Müller UA
    Diabetologia; 2005 Oct; 48(10):1965-70. PubMed ID: 16132954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoglycaemia? Not guilty! Decreased HbA1c? Not guilty!
    Roussel R; Cosson E
    Diabetes Metab; 2010 Feb; 36(1):86-7. PubMed ID: 19716740
    [No Abstract]   [Full Text] [Related]  

  • 36. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe hypoglycaemia in elderly patients with type 2 diabetes and coexistence of cardiovascular history.
    Piątkiewicz P; Buraczewska-Leszczyńska B; Kuczerowski R; Bernat-Karpińska M; Rabijewski M; Kowrach M
    Kardiol Pol; 2016; 74(8):779-785. PubMed ID: 27040016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.
    Heller SR; Geybels MS; Iqbal A; Liu L; Wagner L; Chow E
    Diabetologia; 2022 Jan; 65(1):55-64. PubMed ID: 34704120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.